Ling Ma1, Yan Liang1, Xin Guo1, Ying Wang1, Qi-Bing Xie2. 1. Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China. 2. Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China. qibingxie@126.com.
Abstract
OBJECTIVE: We aimed to convert the English version of the Evaluation of Ankylosing Spondylitis Quality of life (EASi-QoL) into a Chinese version, and to test the reliability and validity of the Chinese version of EASi-QoL. METHODS: The EASi-QoL was translated into Chinese. A total of 127 patients with ankylosing spondylitis (AS) were evaluated using the Chinese version of EASi-QoL to test its validity and reliability. Internal and test-retest reliability was assessed. In addition, correlation and exploratory factor analyses evaluating the structural, convergent, and criterion-related validities of this measure were performed. RESULTS: The total Cronbach's α coefficient of the Chinese version of EASi-QoL was 0.911. The Kaiser-Meyer-Olkin value of the scale in this study was 0.917, and the Bartlett's test value was 2403.499. The convergent validity of the related domains was analyzed using confirmatory factor analysis; and the average variance extracted values corresponding to the four dimensions were all > 0.5, and the composite reliability values were all > 0.7. Discriminative validity analysis showed that the correlation between the four domains of EASi-QoL and their related domains of the depression/anxiety screening scale and the Medical Outcomes study Short-Form 36 were moderate to high. CONCLUSION: The Chinese version of EASi-QoL has high reliability and validity, and can reflect the impact of AS on the quality of life. Key Points • The Chinese version of EASi-QoL can accurately measure the impact of AS on the quality of life from the perspective of a patient. It is applicable to the evaluation of AS patients in China • The Chinese version of EASi-QoL is a scale with good reliability and validity.
OBJECTIVE: We aimed to convert the English version of the Evaluation of Ankylosing Spondylitis Quality of life (EASi-QoL) into a Chinese version, and to test the reliability and validity of the Chinese version of EASi-QoL. METHODS: The EASi-QoL was translated into Chinese. A total of 127 patients with ankylosing spondylitis (AS) were evaluated using the Chinese version of EASi-QoL to test its validity and reliability. Internal and test-retest reliability was assessed. In addition, correlation and exploratory factor analyses evaluating the structural, convergent, and criterion-related validities of this measure were performed. RESULTS: The total Cronbach's α coefficient of the Chinese version of EASi-QoL was 0.911. The Kaiser-Meyer-Olkin value of the scale in this study was 0.917, and the Bartlett's test value was 2403.499. The convergent validity of the related domains was analyzed using confirmatory factor analysis; and the average variance extracted values corresponding to the four dimensions were all > 0.5, and the composite reliability values were all > 0.7. Discriminative validity analysis showed that the correlation between the four domains of EASi-QoL and their related domains of the depression/anxiety screening scale and the Medical Outcomes study Short-Form 36 were moderate to high. CONCLUSION: The Chinese version of EASi-QoL has high reliability and validity, and can reflect the impact of AS on the quality of life. Key Points • The Chinese version of EASi-QoL can accurately measure the impact of AS on the quality of life from the perspective of a patient. It is applicable to the evaluation of AS patients in China • The Chinese version of EASi-QoL is a scale with good reliability and validity.
Authors: Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun Journal: Ann Rheum Dis Date: 2017-01-13 Impact factor: 19.103
Authors: Linda E Dean; Gareth T Jones; Alan G MacDonald; Christina Downham; Roger D Sturrock; Gary J Macfarlane Journal: Rheumatology (Oxford) Date: 2013-12-09 Impact factor: 7.580
Authors: Kirstie L Haywood; Andrew M Garratt; Kelvin P Jordan; Emma L Healey; Jonathan C Packham Journal: J Rheumatol Date: 2010-08-03 Impact factor: 4.666
Authors: Jon C Packham; Kelvin P Jordan; Kirstie L Haywood; Andrew M Garratt; Emma L Healey Journal: Rheumatology (Oxford) Date: 2011-12-16 Impact factor: 7.580
Authors: M A Stone; E Pomeroy; A Keat; R Sengupta; S Hickey; P Dieppe; R Gooberman-Hill; R Mogg; J Richardson; R D Inman Journal: Rheumatology (Oxford) Date: 2008-06-06 Impact factor: 7.580